Business Context and Reporting Period
This Form 8-K Current Report, filed on September 27, 2021, by Precision BioSciences, Inc. (DTIL), announces a significant change in executive leadership. The Board of Directors appointed Michael Amoroso as President and Chief Executive Officer, effective October 15, 2021. Mr. Amoroso succeeds Mathew Kane, who will transition to a non-employee advisor role through October 1, 2022.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- Annual Base Salary: $600,000
- Target Annual Bonus: 60% of base salary ($360,000)
- Signing Bonus: $200,000 (payable with 2021 annual bonuses)
- Relocation Reimbursement: Up to $50,000 (grossed-up for taxes)
- Legal Fee Reimbursement: Up to $10,000
- Initial Stock Option Grant: 850,000 shares (vesting 25% at one year, remainder ratably over three years)
- Subsequent Stock Option Grant: 250,000 shares (granted within 30 days of first anniversary)
- Restricted Stock Units (RSUs): Grant date fair value of $237,000 (vesting at first anniversary)
Material Changes
The primary material change is the departure of Mathew Kane as CEO and the appointment of Michael Amoroso. Mr. Amoroso brings extensive experience from Abeona Therapeutics, Kite Pharma (Gilead), Celgene, and Sanofi, with expertise in rare diseases, oncology, and cell/gene therapies. The filing details the specific compensation package negotiated to secure his services.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or operational outlook. Key contractual terms and contingencies include:
- Termination Provisions: Employment is terminable without cause with 30 days' notice. Termination without cause or for "good reason" triggers 1.0x base salary continuation and 12 months of COBRA coverage.
- Change in Control: If termination occurs within 12 months of a change in control, the executive receives 1.5x base salary plus 1.5x target bonus, 18 months of COBRA, and accelerated vesting of all unvested equity.
- Clawback: The relocation bonus must be repaid if Mr. Amoroso resigns without good reason or is terminated for cause within 12 months of the effective date.
- Non-Compete: A 12-month non-compete and non-solicit period applies post-employment (extended to 18 months if termination occurs within 12 months of a change in control).
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price for the 850,000 initial stock options and 250,000 subsequent options.
- Confirm the total dilution impact of the equity grants (options and RSUs) on existing shareholders.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Assess the transition plan details between Mr. Kane and Mr. Amoroso to ensure operational continuity.